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Carlos Fernandez de Larrea,1 Natalia Tovar,1 Marıa Rozman,2 Laura Rosi~nol,1
Juan Ignacio Arostegui,3 Marıa Teresa Cibeira,1 Montserrat Rovira,1
Jordi Yag€ue,3 Joan Blade1The current definition of complete remission (CR) in multiple myeloma (MM) requires a negative serum and
urine immunofixation (IFE) and\5% bone marrow plasma cells (BMPCs). The aim of this study was to de-
termine the value of BMPCs count by standard microscopic evaluation in patients with MM in serologic CR
after autologous stem cell transplantation (ASCT). Thirty-five patients with a median follow-up after ASCTof
7.3 years were studied. The percentage of BMPCs was an independent predictor of progression in multivar-
iate model (hazard ratio 2.02, P 5 .009). Patients with .1.5% BMPCs (median: 0.8%) after ASCT had an in-
creased risk of progression (P 5 .016) and a trend toward a shorter survival (P 5 .195). In conclusion,
conventional morphology of bonemarrow is a useful and rapid tool as a first step to assess the residual tumor
mass in patients with MM in CR after ASCT, and it constitutes a strong predictor for disease progression.
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plantationINTRODUCTION
The achievement of complete remission (CR) is
the crucial step for a long-lasting response and pro-
longed survival after autologous stem cell transplanta-
tion (ASCT) in patients with multiple myeloma (MM)
[1-3]. The European Group for Blood and Marrow
Transplantation (EBMT) criteria for CR include the
negativity of serum and urine immunofixation (IFE)
and\5% of bone marrow plasma cells (BMPCs) [4].
Additionally, the International Myeloma Working
Group (IMWG) has even proposed a stringent CR
category, which also requires ruling out the clonal
nature of the BMPCs [5]. However, few studies have
addressed this issue in patients with MM and negative1Department of Hematology; 2Hematopathology Unit;
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6/j.bbmt.2010.12.707IFE [6]. Despite the EBMT and IMWG recommenda-
tions, there have been suggestions to eliminate the
bone marrow examination from the clinical practice
in patients with negative IFE, arguing that the 5%
limit is arbitrary, there is uncertainty in its prognostic
value, and that the procedure is uncomfortable for
patients [6]. The aim of the present study was to deter-
mine the impact of plasma cell count in the bone mar-
row aspirate estimated by conventional morphology
on the long-term outcome of patients with MM with
negative IFE after ASCT.MATERIALS AND METHODS
Thirty-five patients (16 M/19 F; median age at
ASCT 55 years, range: 26-68) with symptomatic
MM who underwent ASCT from March 31, 1994, to
August 29, 2008, with available bone marrow aspirates
and adequate cellularity were included in the study. All
patients had achieved a negative serum and urine IFE
after high-dose therapy with melphalan-based regi-
mens (melphalan 200 mg/m2, melphalan 140 mg/m2
plus total-body irridiation [TBI], or melphalan 140
mg/m2 plus busulfan 12 mg/kg) (Table 1).
Bone marrow aspiration was performed when neg-
ative serum and urine IFE was achieved and at least 3
Table 1. Patient Characteristics
Value
Median age, years. (range) 55 (26-68)
Male/female, no. 16/19
M-protein type (%)
IgG 42.9
IgA 22.9
Light chain only 25.7
IgD 5.7
IgM 2.9
Light-chain type (%)
k 57.1
l 42.9
Durie-Salmon stage at diagnostic (%)*
I 11.8
II 38.2
III 50.0
Initial chemotherapy (%)†
VMCP/VBAP or VBMCP/VBAD 60.0
Other 40.0
HDT regimen
Mel-200 71.4
BU/MEL 17.2
Mel-140/TBI 11.4
TBI indicates total-body irridiation; V(B)MCP, vincristine; (BCNU), mel-
phalan, cyclophosphamide, prednisone; VBAD(P), vincristine, BCNU
doxorubicin, dexamethasone (prednisone); HDT, high-dose therapy;
Mel-200, melphalan 200 mg/m2; BU/MEL, melphalan 140 mg/m2 plus
busulfan 12 mg/kg; Mel-140/TBI, melphalan 140 mg/m2 plus total-body
irradiation.
*Durie-Salmon stage was available in 34 patients.
†One patient did not receive induction chemotherapy because of asso-
ciated primary amyloidosis (AL).
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2-11). The analysis was based on microscopic revision
of May-Gr€unwald–Giemsa–stained bone marrow
smears performed according to standard procedures.
BMPC percentage was calculated independently by 2
observers (C.F.d.L. or N.T., and the senior cytologist
M.Rozman.) counting 500 bone marrow total nucle-
ated cells in random areas from 2 different slides
(1000 cells from each patient). The evaluation was re-
peated in 7 patients (20%) because of a discordance
$0.5% BMPCs between the 2 observers. In all cases,
a new independent revision of 500 cells by each ob-
server resulted in a concordance with\0.5% differ-
ence. Baseline demographics, clinical and laboratory
data, as well as induction treatment were collected
from all patients. Progression-free survival (PFS) was
defined as survival from ASCT until relapse or dead
from any cause. Overall survival (OS) was calculated
from the time of ASCT. IFE was performed every 6
months in patients in CR after ASCT. The median
follow-up of the series was 7.3 years, and no patient
was lost to follow-up.RESULTS AND DISCUSSION
The initial clinical and laboratory findings as well
as the induction chemotherapy and the high-doseregimen are shown in Table 1. All 35 patients had
available bone marrow aspirates with adequate cellu-
larity. Median BMPCs percentage was 0.8 (range:
0.1-5.8). Only 2 patients had.3% BPMCs. These re-
sults are in contrast with a recent report from theMayo
Clinic group, where 14% of the patients with MM and
negative IFE had 5% or more BMPCs [6]. The dis-
crepancy between our results and those reported by
the Mayo group could be explained by several reasons.
First, the study population in theMayo report was het-
erogeneous. Thus, 55% of the patients had achieved
negative IFE after ASCT whereas the remaining
45% were in CR after conventional chemotherapy.
Additionally, the BMPCs percentages were not ana-
lyzed separately according to the treatment adminis-
tered. In contrast, all our patients were in CR after
ASCT. In fact, the extremely low percentage of
BMPCs in our patients in CR is surprising, and it is
likely related to the myeloablative high-dose treatment
with its possible effect on the myeloma stem cell. Sec-
ond, the estimation of BMPCs in the Mayo study was
not based on a systematic count by independent ob-
servers on a large number of cells. Third, the estima-
tion of BMPCs was made on bone marrow aspirate
and biopsy in the Mayo report versus the assessment
only in bone marrow aspiration in the present study,
which could have resulted in underestimation of the
proportion of BMPCs in our series.
In univariate Cox model regression analysis, the
number of BMPCs showed a significant correlation
with PFS (P 5 .021) with no significant impact on
OS (P 5 .92). This statistical significance on PFS
was retained in themultivariate analysis, when baseline
prognostic factors such as age, hemoglobin level, se-
rum creatinine, b2-microglobulin, Durie-Salmon
stage, or conditioning regimen were added to the
model (hazard ratio [HR] 2.02, P 5 .009). For
Kaplan-Meier survival analysis [7], patients were di-
vided according to BMPC percentage into 3 groups
(group 1:\1%, group 2: between 1% and 2%, and
group 3: .2%). The PFS was significantly longer in
the 2 first groups compared with group 3 (log-rank
test, P 5 .01), with no significant difference in OS.
To establish the best predictive cutoff for progression
and survival, a receiver-operator curve (ROC) analysis
was developed [8,9]. It showed the value of 1.5%
BMPCs, with a sensitivity of 53%, specificity of
90%, and area under the curve (AUC) of 0.66 for
predicting progression. Ten patients had .1.5%
BMPC, and 25 #1.5% BMPC. Median PFS was 8.5
years (confidence interval [CI] 95% 2.6-14.3) and
was not reached in patients with #1.5% BMPCs
versus 3.1 years in patients with .1.5% BMPCs,
with a hazard ratio probability to progression of 3.02
(CI 95% 1.18-9.71) (P 5 .016) in the group with
.1.5% of BMPCs (Figure 1). Of interest, the median
BMPC count was similar in patients who received
Figure 1. Progression-free survival (PFS) in patients with MMwith neg-
ative immunofixation electrophoresis after ASCT, according to number
of bone marrow plasma cells (BMPCs).
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(1.16% versus 1.27%, P 5 .8) and the proportion of
patients with.1.5% BMPCs was not significantly dif-
ferent (24% versus 33%, P5 .67). PFS was also similar
with the 2 induction groups (P5 .36). Median OS was
not reached in patients with #1.5% compared with
a median of 9.7 years in those with more than 1.5%
BMPCs (P 5 .195) (Figure 2). The lack of influence
of the proportion of BMPCs on OS could be explained
by the impact of rescue regimens after relapse and also
for the small number of patients included in our study.
These results on the prognostic value of BMPCs in pa-
tients in CR are in agreement with those reported in
the Mayo Clinic study [6], but with a much lower
BMPC cutoff in our series (1.5% instead of 5%). Mo-
lecular studies performed on small series of patients
have shown that the level of residual clonal plasma cellsFigure 2. Overall survival (OS) in patients with MM with negative im-
munofixation electrophoresis after ASCT, according to number of bone
marrow plasma cells (BMPCs).correlate with long-term outcome after hematopoietic
stem cell transplantation [10-12]. In addition, 4 studies
have shown that minimal residual disease (MRD)
defined by multiparameter flow cytometry (MFC) is
more sensitive than IFE [13-16]. In the largest of
these studies, MRD detected by MFC emerged as
the most relevant prognostic factor [16]. Of note, in
the study by Paiva et al. [16], the median percentage
of total BMPCs seen by immunophenotyping was as
low as 0.26%, a figure that is equivalent (about one-
third) to the 0.8% observed in the present study by
conventional bone marrow examination, explained by
the different distribution of BM cells in samples for
both techniques [17]. Interestingly, our results on
PFS (median not reached versus 37 months) and OS
(median not reached versus 116 months) with the
BMPCs cutoff at 1.5% are very close to those reported
by Paiva et al. [16], based on the absence or presence of
MRD by MFC with median PFS of 71 versus 37
months and median OS not reached versus 89 months.
It is likely that serologic CR with very low percentage
of BMPCs (ie,#1.5%) is equivalent to negative MRD
by MFC or molecular remission. In fact, all our 8 pa-
tients in continued CR between 9 and 16 years beyond
ASCT (‘‘operational cures’’ [18,19]) are in the group
with #1.5% BMPCs, whereas all patients in the
group with .1.5% BPMC have relapsed within the
first 9 years from ASCT (Figure 1). Needless to say,
the immunophenotypic and, particularly, molecular
remission represent an upgraded level of response
than the IFE negative CR and must be the ultimate
goal of myeloma therapy.
In summary, our results show that the percentage
of BMPCs in patients with MM in CR after ASCT is
a strong predictor of progression. Our observation is
in line with recent reports on the prognostic value of
MRD assessment either by MFC or molecular studies.
Bone marrow morphology examination is an easy, in-
expensive, and nontime-consuming test, and it should
be the first step in the estimation of the residual tumor
mass in patients with MM and negative immunofixa-
tion after ASCT.ACKNOWLEDGMENTS
Financial disclosure: This work has been supported
in part by grants RD06/0020/0005, CM07/00108,
and FIS08/0147 from Instituto de Salud Carlos III;
and ‘‘Josep Font’’ Grant from Hospital Clınic de Bar-
celona.AUTHORSHIP STATEMENT
C.F.L. and J.B. designed the research, collected
and analyzed data, performed statistical analysis, wrote
and reviewed the paper. C.F.L., N.T. and M.R.
Biol Blood Marrow Transplant 17:1084-1087, 2011 1087BMPCs and Outcome in MM in CR after ASCT(M. Rozman) performed the bone marrow plasma cell
counts. N.T. and M.R. (M. Rozman) collected data
and reviewed the paper. M.T.C., L.R. and M.R.
(M. Rovira) treated the patients, collected data and re-
viewed the paper. J.I.A. and J.Y. performed the immu-
nofixation assays and reviewed. All the authors
approved the final version of the manuscript.REFERENCES
1. Lahuerta JJ, Mateos MV, Martınez-Lopez J, et al. Influence of
pre- and post-transplantation responses on outcome of patients
with multiple myeloma: sequential improvement of response
and achievement of complete response are associated with lon-
ger survival. J Clin Oncol. 2008;26:5775-5782.
2. Wang M, Delasalle K, Feng L, et al. CR represents an early in-
dex of potential long survival in multiple myeloma. Bone Marrow
Transplant. 2010;45:498-504.
3. van de Velde HJ, Liu X, Chen G, Cakana A, Deraedt W,
Bayssas M. Complete response correlates with long-term sur-
vival and progression-free survival in high-dose therapy in mul-
tiple myeloma. Haematologica. 2007;92:1399-1406.
4. Blade J, SamsonD, ReeceD, et al. Criteria for evaluating disease
response and progression in patients with multiple myeloma
treated by high-dose therapy and haemopoietic stem cell trans-
plantation. Myeloma Subcommittee of the EBMT. European
Group for Blood and Marrow Transplant. Br J Haematol.
1998;102:1115-1123.
5. Durie BG, Harousseau JL, Miguel JS, et al. International uni-
form response criteria for multiple myeloma. Leukemia. 2006;
20:1467-1473.
6. CheeCE,Kumar S,LarsonD, et al. The importance of bonemar-
row examination in determining complete response to therapy
in patients with multiple myeloma. Blood. 2009;114:2617-2618.
7. Bland JM, AltmanDG. Survival probabilities (the Kaplan-Meier
method). BMJ. 1998;317:1572.
8. Hanley JA, McNeil BJ. The meaning and use of the area under
a receiver operating characteristic (ROC) curve. Radiology. 1982;
143:29-36.
9. N€uckel H, Rebmann V, D€urig J, D€uhrsen U, Grosse-Wilde H.
HLA-G expression is associated with an unfavorable outcomeand immunodeficiency in chronic lymphocytic leukemia. Blood.
2005;105:1694-1698.
10. Sarasquete ME, Garcıa-Sanz R, Gonzalez D, et al. Minimal re-
sidual disease monitoring in multiple myeloma: a comparison
between allelic-specific oligonucleotide real-time quantitative
polymerase chain reaction and flow cytometry. Haematologica.
2005;90:1365-1372.
11. Martinelli G, Terragna C, Zamagni E, et al. Polymerase chain
reaction-based detection of minimal residual disease in multiple
myeloma patients receiving allogeneic stem cell transplantation.
Haematologica. 2000;8:930-934.
12. Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking
and persistent molecular remissions after consolidation with
bortezomib, thalidomide, and dexamethasone in patients with
autografted myeloma. J Clin Oncol. 2010;28:2077-2084.
13. San Miguel JF, Almeida J, Mateo G, et al. Immunophenotypic
evaluation of the plasma cell compartment in multiple myeloma:
a tool for comparing the efficacy of different treatment strategies
and predicting outcome. Blood. 2002;99:1853-1856.
14. Liu H, Yuan C, Heinerich J, et al. Flow cytometric minimal
residual disease monitoring in patients with multiple myeloma
undergoing autologous stem cell transplantation: a retrospective
study. Leuk Lymphoma. 2008;49:306-314.
15. Rawstron AC, Davies FE, DasGupta R, et al. Flow cytometric
disease monitoring in multiple myeloma: the relationship be-
tween normal and neoplastic plasma cells predicts outcome after
transplantation. Blood. 2002;100:3095-3100.
16. Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow
cytometric remission is the most relevant prognostic factor for
multiple myeloma patients who undergo autologous stem cell
transplantation. Blood. 2008;112:4017-4023.
17. Paiva B, Vidriales MB, Perez JJ, et al. Multiparameter flow cy-
tometry quantification of bone marrow plasma cells at diagnosis
provides more prognostic information than morphological
assessment in myeloma patients. Haematologica. 2009;94:
1599-1602.
18. Barlogie B, Tricot GJ, van Rhee F, et al. Long-term outcome re-
sults of the first tandem autotransplant trial for multiple mye-
loma. Br J Haematol. 2006;135:158-164.
19. Rovira M, Rosi~nol L, Fernandez-Aviles F, et al. Is there a
curative potential of autologous stem cell transplantation in
multiple myeloma? Long-term results from a single-centre se-
ries [abstract]. Bone Marrow Transplant. 2009;43:S147. Abstract
no. P592.
